Literature DB >> 23378125

Hospital admission decision for patients with community-acquired pneumonia.

Stefano Aliberti1, Paola Faverio, Francesco Blasi.   

Abstract

Where to treat patients is probably the single most important decision in the management of community-acquired pneumonia (CAP), with a substantial impact on both patients' outcomes and health-care costs. Several factors can contribute to the decision of the site of care for CAP patients, including physicians' experience and clinical judgment and severity scores developed to predict mortality, as well as social and health-care-related issues. The recognition, both in the community and in the emergency department, of the presence of severe sepsis and acute respiratory failure and the coexistence with unstable comorbidities other than CAP are indications for hospital admission. In all the other cases, physician's choice to admit CAP patients should be validated against at least one objective tool of risk assessment, with a clear understanding of each score's limitations.

Entities:  

Year:  2013        PMID: 23378125     DOI: 10.1007/s11908-013-0323-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  85 in total

Review 1.  Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis.

Authors:  Maggie McNally; James Curtain; Kirsty K O'Brien; Borislav D Dimitrov; Tom Fahey
Journal:  Br J Gen Pract       Date:  2010-10       Impact factor: 5.386

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia.

Authors:  Stefano Aliberti; Asad Amir; Paula Peyrani; Mehdi Mirsaeidi; Marty Allen; Brian K Moffett; John Myers; Fidaa Shaib; Maria Cirino; Jose Bordon; Francesco Blasi; Julio A Ramirez
Journal:  Chest       Date:  2008-06-26       Impact factor: 9.410

4.  Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care.

Authors:  James D Chalmers; Joanne K Taylor; Pallavi Mandal; Gourab Choudhury; Aran Singanayagam; Ahsan R Akram; Adam T Hill
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

5.  Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study.

Authors:  Bertrand Renaud; Eva Coma; Jose Labarere; Jan Hayon; Pierre-Marie Roy; Hélène Boureaux; Fabienne Moritz; Jean François Cibien; Thomas Guérin; Emmanuel Carré; Armelle Lafontaine; Marie Pierre Bertrand; Aline Santin; Christian Brun-Buisson; Michael J Fine; Eric Roupie
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

6.  Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia.

Authors:  Drahomir Aujesky; Julie B McCausland; Jeff Whittle; D Scott Obrosky; Donald M Yealy; Michael J Fine
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

7.  Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia.

Authors:  Mirjam Christ-Crain; Daiana Stolz; Sukhdeep Jutla; Orestes Couppis; Christian Müller; Roland Bingisser; Philipp Schuetz; Michael Tamm; Ray Edwards; Beat Müller; Ashley B Grossman
Journal:  Am J Respir Crit Care Med       Date:  2007-08-16       Impact factor: 21.405

8.  Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial.

Authors:  S J Atlas; T I Benzer; L H Borowsky; Y Chang; D C Burnham; J P Metlay; E A Halm; D E Singer
Journal:  Arch Intern Med       Date:  1998-06-22

9.  Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.

Authors:  David T Huang; Derek C Angus; John A Kellum; Nathan A Pugh; Lisa A Weissfeld; Joachim Struck; Russell L Delude; Matthew R Rosengart; Donald M Yealy
Journal:  Chest       Date:  2009-04-10       Impact factor: 9.410

10.  Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study.

Authors:  Martin Kolditz; Gert Höffken; Peter Martus; Gernot Rohde; Hartwig Schütte; Robert Bals; Norbert Suttorp; Mathias W Pletz
Journal:  BMC Infect Dis       Date:  2012-04-13       Impact factor: 3.090

View more
  3 in total

1.  CDS in a Learning Health Care System: Identifying Physicians' Reasons for Rejection of Best-Practice Recommendations in Pneumonia through Computerized Clinical Decision Support.

Authors:  Barbara E Jones; Dave S Collingridge; Caroline G Vines; Herman Post; John Holmen; Todd L Allen; Peter Haug; Charlene R Weir; Nathan C Dean
Journal:  Appl Clin Inform       Date:  2019-01-02       Impact factor: 2.342

Review 2.  The management of community-acquired pneumonia in the elderly.

Authors:  Paola Faverio; Stefano Aliberti; Giuseppe Bellelli; Giulia Suigo; Sara Lonni; Alberto Pesci; Marcos I Restrepo
Journal:  Eur J Intern Med       Date:  2013-12-17       Impact factor: 4.487

3.  Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis.

Authors:  Stefano Aliberti; Anna Maria Brambilla; James D Chalmers; Catia Cilloniz; Julio Ramirez; Angelo Bignamini; Elena Prina; Eva Polverino; Paolo Tarsia; Alberto Pesci; Antoni Torres; Francesco Blasi; Roberto Cosentini
Journal:  Respir Res       Date:  2014-03-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.